Form 4: Standex Director Sells Shares Under 10b5-1 Plan

Standex International Director Thomas E. Chorman reported the sale of 50 common shares at $259 each, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Thomas E. Chorman, a Director at Standex International Corporation (SXI), reported a transaction involving the company's common stock.
• On March 2, 2026, Chorman disposed of 50 shares of common stock.
• The shares were sold at a price of $259 per share.
• This sale was conducted pursuant to an existing Rule 10b5-1 trading plan, which was established on November 6, 2025.
• Following this transaction, Chorman beneficially owns 12,616 shares of Standex International common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is part of a pre-arranged 10b5-1 plan, which typically indicates personal financial planning rather than a negative signal about the company's performance or outlook.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than an immediate reaction to new information.

Negatives

• A director's sale of shares, even under a 10b5-1 plan, reduces their direct ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common practice for executives and directors to manage their personal portfolios and diversify holdings while avoiding accusations of trading on material non-public information. Such pre-scheduled sales are generally viewed as less indicative of management's sentiment about the company's future prospects compared to unscheduled, open-market sales.

Stakeholder Impact

• Shareholders: A minor reduction in director ownership, but mitigated by the 10b5-1 plan. No direct impact on company operations or financial health.

Key Dates

Recommendation

The transaction is a routine, pre-scheduled sale under a 10b5-1 plan, which does not typically signal a change in the company's fundamentals or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Standex International, SXI, Form 4, Insider Trading, Stock Sale, Director Transaction, 10b5-1 Plan, Thomas E. Chorman, Equity Disclosure